Top 20 of Drug Eruptions

Article title # Publications/# Citations

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

2001: CDBritten; LDenis; SGEckhardt; KFerrante; LAHammond; MHidalgo; JNemunaitis; JRizzo; ... EKRowinsky; SSilberman; LLSiu; CTakimoto; ATolcher; DDVon Hoff;


Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.

1984: JWHiemenz; CHonig; JAKovacs; HCLane; DLLongo; AMMacher; HWMurray; JShelhamer; DStöver; CUrmacher;


Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.

2004: JAMitchell; TDWarner;


Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia.

2004: PBohlen; MDetmar; EFiebiger; DHicklin; SHirakawa; YKHong; RKunstfeld; BLange-Asschenfeldt; ... CLin; VSchacht; PVelasco; XWei; YWu;


A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy.

2008: RAllen; AAAmato; TAraujo; RJBarohn; KBushby; CCsimma; MEagle; DMEscolar; ... KMFlanigan; JLFleckenstein; JMFlorence; PJuneau; WMKing; ERLavallie; JRMendell; KMeyers; SPandya; SAParsons; APestronk; VStraub; RTawil; KRWagner; GIWolfe; JMWozney;


Severe adverse cutaneous reactions to drugs.

1994: JCRoujeau; RSStern;


Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

2011: Protégé Trial Investigators; SAronoff; BBode; EBonvini; DCarlin; AGDaifotis; RJFerry; WHagopian; ... KCHerold; CHolland; SMJain; SJohnson; KLKing; SKoenig; JLudvigsson; SPillemer; NSherry; KEStein; JWahlen; RLWilder;


Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome.

1984: FMGordin; JMills; GLSimon; CBWofsy;


Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.

2003: DMenzies; IParisien; MPelletier; IRocher; CValiquette; DYee;


Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity.

1974: LPolák; JLTurk;


Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.

2001: AAGabizon;


Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981.

1983: BFFarber; RCMoellering;


AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.

2003: North American AA2500 T Gel Study Group; RBachand; KJacoby; SSchwartz; TSebree; TSmith; CSteidle;


Tuberculosis and human immunodeficiency virus infection in developing countries.

1990: ADHarries;


Unwanted effects of propranolol.

1966: SAStephen;


High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.

2007: RAllen; JDBerlin; RMGoldberg; DTMoore; BHO'Neil; DRSpigel; TEStinchcombe;


Cutaneous and ocular reactions to practolol.

1974: MGDahl; RHFélix; FAIve;


Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.

1997: LABeck; MACarducci; SMClift; LKCohen; GDranoff; CCFinn; KMHauda; EMJaffee; ... AJLazenby; KMLeiferman; HILevitsky; FFMarshall; RCMulligan; WGNelson; AHOwens; DMPardoll; SPiantadosi; JWSimons; CEWeber;


Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.

2008: MFerrante; HFidder; LHenckaerts; KKatsanos; MNoman; PRutgeerts; FSchnitzler; SSegaert; GVan Assche; SVermeire;


Practical management of patients with chronic myeloid leukemia receiving imatinib.

2003: MWDeininger; BJDruker; JMFord; SGO'Brien;